TABLE 3.
Pooled random-effects IR and RR for cancer and cardiovascular outcomes in new users of CE/BZA and new users of EP
| CE/BZA (n = 10,596) | EP (n = 33,818) | CE/BZA vs EP (ref) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | PY | IRp (95% CI)a | Q | I 2b | Cases | PY | IRp (95% CI)a | Q | I 2b | RRp (95% CI) | Q | I 2b | |
| Endometrial outcomes | |||||||||||||
| Endometrial cancer | 12 | 19,704 | 5.2 (2.0-8.4) | 3.3 | 0 | 27 | 62,754 | 3.6 (1.1-6.1) | 8.5 | 52.6 | 1.5 (0.8-2.9) | 0.6 | 0 |
| Endometrial hyperplasiad | 14 | 9,689 | 11.0 (1.8-20.2) | 5.9 | 31.8 | 34 | 29,081 | 10.6 (6.1-15.1) | 4.8 | 15.7 | 1.7 (0.5-5.6) | 8.2 | 51.3 |
| Extrauterine outcomes | |||||||||||||
| Any cancerc | 140 | 19,487 | 71.6 (59.7-83.5) | 1 | 0 | 478 | 62,066 | 76.7 (69.8-83.6) | 2.1 | 0 | 0.9 (0.8-1.1) | 0.5 | 0 |
| Breast cancer | 55 | 19,625 | 27.2 (19.9-34.5) | 2.1 | 0 | 231 | 62,422 | 36.3 (30.4-42.2) | 5 | 20.5 | 0.8 (0.6-1.1) | 3.5 | 0 |
| Ovarian cancer | 5 | 19,693 | 2.1 (0.1-4.1) | 1.8 | 0 | 10 | 62,741 | 1.6 (0.6-2.6) | 1.1 | 0 | 1.9 (0.7-5.5) | 2.5 | 0 |
| Thyroid cancer | 13 | 19,677 | 5.9 (2.5-9.2) | 2.5 | 0 | 30 | 62,717 | 4.7 (3.0-6.3) | 1.8 | 0 | 1.5 (0.8-2.9) | 1.9 | 0 |
| Renal cancer or adenoma | 1 | 19,707 | 0.7 (0.0-1.9) | 1.6 | 0 | 8 | 62,756 | 0.9 (0.2-1.7) | 2.7 | 0 | 1.1 (0.3-4.0) | 0.9 | 0 |
| GI cancer | 11 | 19,702 | 4.9 (1.8-8.1) | 1.8 | 0 | 48 | 62,712 | 7.5 (5.4-9.7) | 1.2 | 0 | 0.8 (0.4-1.5) | 1.9 | 0 |
| VTEd | 4 | 9,725 | 3.3 (0.0-6.8) | 2.3 | 0 | 13 | 29,188 | 3.6 (0.7-6.5) | 5.4 | 26.2 | 1.3 (0.5-3.5) | 1.4 | 0 |
| Myocardial Infarctiond | 3 | 9,353 | 3.9 (0.0-7.9) | 0.8 | 0 | 11 | 27,966 | 3.3 (1.2-5.4) | 2.8 | 0 | 1.2 (0.4-3.8) | 1.6 | 0 |
| Stroke/TIAd | 15 | 9,348 | 14.0 (1.0-27.1) | 7.7 | 48.2 | 41 | 27,954 | 13.4 (7.1-19.6) | 6.2 | 34.9 | 1.2 (0.7-2.1) | 1.6 | 0 |
CE/BZA, conjugated estrogens/bazedoxifene; CI, confidence interval; EP, estrogen-progestin hormone therapy; GI, gastrointestinal; IR, incidence rate; IRp, pooled incidence rate; n, number; PY, person-years; RR, incidence rate ratio; RRp, pooled incidence rate ratio; ref, referent; TIA, transient ischemic attack; VTE, venous thromboembolism.
aPer 10,000 PY. IR values were pooled independently from RR values; as a result, the CE/BZA IRp divided by the EP IRp may not equate to the RRp.
bDisplayed as %.
cAny cancer except nonmelanoma skin cancer.
dNoncancer outcomes were censored by the end of current treatment episode.